NORDIC BIOTECH ADVISORS ApS: Financial statements 2022
CVR: 26123925
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
NORDIC BIOTECH ADVISORS ApS (CVR 26123925) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 3,812,316 and a net result of DKK 942,698 compared with DKK 657,338 the year before. That is an increase of 3% compared with the year before. Equity in the 2022 report amounted to DKK 3,401,818. The solvency ratio was 79.8%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 3,812,316
- Profit/Loss
- DKK 942,698
- Equity
- DKK 3,401,818
- Total Assets
- DKK 4,260,951
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 3.8M | 943K | 3.4M | 2 |
| 2021 | - | 3.7M | 657K | 2.5M | 2 |
| 2020 | - | 2.7M | -301K | 1.8M | 2 |
| 2019 | - | 3.3M | 81K | 2.1M | 2 |
| 2018 | - | 3.4M | -119K | 2M | 1 |
Official annual report
Keep an eye on NORDIC BIOTECH ADVISORS ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
NORDIC BIOTECH ADVISORS ApS has published its annual report for 2021. Gross profit came to DKK 3,700,141, and the net result was DKK 657,338.
About NORDIC BIOTECH ADVISORS ApS
NORDIC BIOTECH ADVISORS ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2001. The company is registered under the industry Andre aktiviteter i forbindelse med finansielle tjenesteydelser, undtagen forsikring og pensionsforsikring. The company was previously named NEXGEN BIOTECH ApS and NORDIC BIOTECH ApS. The management consists of Florian Schønharting. The board consists of Florian Schønharting and Jakob Mosegaard Larsen. The company is owned by TECH GROWTH INVEST ApS, C. HANSEN INVEST ApS and BVF/Nexgen Biotech, LP. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,273,154 and a net result of DKK 360,368 compared with DKK -572,578 the year before. Equity in the 2025 report amounted to DKK 4,622,219.
